OM
TGTX icon

Opaleye Management’s TG Therapeutics TGTX Stock Holding History

Opaleye Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.8M Hold
535,000
– – 2.34% 14
2025
Q4 		$15.9M Hold
535,000
– – 2.1% 11
2025
Q3 		$19.3M Hold
535,000
– – 2.73% 8
2025
Q2 		$19.3M Hold
535,000
– – 3.9% 8
2025
Q1 		$21.1M Sell
535,000
-1,725,000
-76% -$58M 4.7% 8
2024
Q4 		$68M Sell
2,260,000
-20,000
-0.9% -$574K 11.9% 2
2024
Q3 		$53.3M Hold
2,280,000
– – 8.89% 2
2024
Q2 		$40.6M Hold
2,280,000
– – 9.27% 2
2024
Q1 		$34.7M Buy
2,280,000
+65,000
+3% +$1.04M 7.56% 3
2023
Q4 		$37.8M Buy
2,215,000
+325,000
+17% +$3.78M 10.06% 2
2023
Q3 		$15.8M Buy
+1,890,000
New +$26.3M 5.14% 4
2021
Q1 		– Sell
-387,500
Closed -$20.2M – 66
2020
Q4 		$20.2M Sell
387,500
-2,500
-0.6% -$84.5K 2.63% 11
2020
Q3 		$10.4M Sell
390,000
-66,600
-15% -$1.53M 2.04% 18
2020
Q2 		$8.89M Sell
456,600
-36,400
-7% -$586K 1.8% 18
2020
Q1 		$4.85M Sell
493,000
-86,651
-15% -$1.09M 1.29% 25
2019
Q4 		$6.43M Sell
579,651
-32,849
-5% -$250K 1.26% 35
2019
Q3 		$3.44M Sell
612,500
-537,500
-47% -$3.75M 1.24% 30
2019
Q2 		$9.95M Sell
1,150,000
-216,062
-16% -$1.63M 3.03% 14
2019
Q1 		$11M Buy
1,366,062
+816,062
+148% +$4.41M 3.04% 8
2018
Q4 		$2.25M Buy
550,000
+200,000
+57% +$994K 0.84% 32
2018
Q3 		$1.96M Sell
350,000
-275,000
-44% -$3.14M 0.5% 38
2018
Q2 		$8.22M Buy
625,000
+350,800
+128% +$4.82M 2.13% 13
2018
Q1 		$3.89M Buy
+274,200
New +$3.5M 1.11% 28
2016
Q3 		– Sell
-175,000
Closed -$1.06M – 51
2016
Q2 		$1.06M Sell
175,000
-240,000
-58% -$1.95M 0.71% 44
2016
Q1 		$3.54M Buy
415,000
+115,000
+38% +$1.01M 2.21% 20
2015
Q4 		$3.58M Buy
300,000
+40,000
+15% +$505K 1.5% 29
2015
Q3 		$2.62M Buy
+260,000
New +$3.87M 1.29% 32

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Opaleye Management's TGTX Position: Q1 2026 in Review

Opaleye Management held its TG Therapeutics (TGTX) position steady in Q1 2026 at 535,000 shares worth $17.8M. The position accounts for 2.34% of the portfolio, ranked #14.

Opaleye Management first reported a position in TGTX in Q3 2015 and has held it in 27 quarters since. The position peaked at $68M in Q4 2024. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Opaleye Management held 535,000 shares of TG Therapeutics worth $17.8M as of Q1 2026.
  • Opaleye Management left its TG Therapeutics share count unchanged in Q1 2026.
  • TG Therapeutics made up 2.34% of Opaleye Management's portfolio in Q1 2026, its #14 holding.
  • Opaleye Management first reported a position in TG Therapeutics in Q3 2015 and has held it in 27 quarters since.
  • Opaleye Management's TG Therapeutics position peaked at $68M in Q4 2024.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.